Compare AbbVie Inc (ABBV) vs NetApp Inc. (NTAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs NetApp Inc. — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while NetApp Inc. trades at $164.68 (market cap $32.48B). The key difference: AbbVie Inc is far larger — about 13.9× NetApp Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | NTAP | |
|---|---|---|
Market Cap | $449.91B | $32.48B |
Sector | Health | Technology |
52-Week High | $261.07 | $181.08 |
52-Week Low | $184.85 | $94.11 |
Enterprise Value | $513.38B | $31.63B |
Dividend Yield | 2.72% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
NTAP trades at $165.78, up 7.53% in the last session, near its consensus price target of $167.45. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical signals from moving averages. Revenue grew to $6.57B in 2025 with an 18.43% net income margin, while cash flow turned positive at $840M. Recent news highlights AI-driven growth opportunities and strategic partnerships enhancing its data infrastructure offerings.
The outlook remains positive given AI demand tailwinds and solid execution, though valuation multiples are elevated. Key risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus leans neutral with a slight buy bias, suggesting cautious optimism for further upside if growth sustains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
